News Archive
9 Dec 2014
Gynesonics Announces Another Peer-Reviewed Publication and Presentation of Significant International Clinical Experience With Vizablate Technology for Symptomatic Uterine Fibroids
5 Dec 2014
Abingworth appoints Kurt von Emster as a Partner In Menlo Park
24 Nov 2014
BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock
4 Nov 2014
Sientra® Announces Closing of Initial Public Offering
30 Oct 2014
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals
15 Oct 2014
ABILITY Network to acquire MD-Online Inc
1 Oct 2014
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
10 Jul 2014
Abingworth Promotes Ken Haas and Vin Miles to Partners
1 Jul 2014
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement
1 Jul 2014
Paratek appoints Michael Bigham as Chairman and CEO and promotes Evan Loh to President and CMO
17 Jun 2014
Pixium Vision raises €34.5 million (US$ 46.7 million) in successful IPO on Euronext Paris, after full exercise of the extension clause
16 Jun 2014
Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors
5 Jun 2014
Senseonics Raises $20 Million; Brings in New VP of Sales and Marketing
31 May 2014
Lenvatinib Phase III Results Show Significant Improvement in Progression-Free Survival in Patients with Radioiodine-refractory Differentiated Thyroid Cancer
16 May 2014
Proteon Therapeutics Announces $45 Million of Series D Financing
6 May 2014
Avillion Announces Royalty Pharma Investment
22 Apr 2014
Gynesonics Names Christopher M. Owens President, Chief Executive Officer
16 Apr 2014
Wilson Therapeutics Secures $40 Million Private Financing to Advance Late Stage Development Program for Wilson's Disease
26 Mar 2014
Pixium Vision appoints Khalid Ishaque as Chief Executive Officer
28 Feb 2014
Abingworth raises £225m ($375m) in its tenth
18 Feb 2014
Avillion appoints Dr Allison Jeynes-Ellis as Chief Executive Officer
3 Feb 2014
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
3 Feb 2014
Ablynx Announces Worldwide Cancer Immunotherapy Discovery Collaboration and Licensing Agreement with Merck
9 Jan 2014
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

 

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
News Archive
9 Dec 2014
Gynesonics Announces Another Peer-Reviewed Publication and Presentation of Significant International Clinical Experience With Vizablate Technology for Symptomatic Uterine Fibroids
5 Dec 2014
Abingworth appoints Kurt von Emster as a Partner In Menlo Park
24 Nov 2014
BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock
4 Nov 2014
Sientra® Announces Closing of Initial Public Offering
30 Oct 2014
Paratek Pharmaceuticals Completes Merger With Transcept Pharmaceuticals
15 Oct 2014
ABILITY Network to acquire MD-Online Inc
1 Oct 2014
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
10 Jul 2014
Abingworth Promotes Ken Haas and Vin Miles to Partners
1 Jul 2014
Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement
1 Jul 2014
Paratek appoints Michael Bigham as Chairman and CEO and promotes Evan Loh to President and CMO
17 Jun 2014
Pixium Vision raises €34.5 million (US$ 46.7 million) in successful IPO on Euronext Paris, after full exercise of the extension clause
16 Jun 2014
Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors
5 Jun 2014
Senseonics Raises $20 Million; Brings in New VP of Sales and Marketing
31 May 2014
Lenvatinib Phase III Results Show Significant Improvement in Progression-Free Survival in Patients with Radioiodine-refractory Differentiated Thyroid Cancer
16 May 2014
Proteon Therapeutics Announces $45 Million of Series D Financing
6 May 2014
Avillion Announces Royalty Pharma Investment
22 Apr 2014
Gynesonics Names Christopher M. Owens President, Chief Executive Officer
16 Apr 2014
Wilson Therapeutics Secures $40 Million Private Financing to Advance Late Stage Development Program for Wilson's Disease
26 Mar 2014
Pixium Vision appoints Khalid Ishaque as Chief Executive Officer
28 Feb 2014
Abingworth raises £225m ($375m) in its tenth
18 Feb 2014
Avillion appoints Dr Allison Jeynes-Ellis as Chief Executive Officer
3 Feb 2014
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
3 Feb 2014
Ablynx Announces Worldwide Cancer Immunotherapy Discovery Collaboration and Licensing Agreement with Merck
9 Jan 2014
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
 
Copyright Abingworth 2017